The CEO/CFO's concentrated buying over five days is a bullish signal for a small-cap biotech, especially given the 88% analyst bullishness and the company's focus on the GP2 breast cancer vaccine. Monitor for upcoming clinical data readouts or regulatory updates that could catalyze the stock. The small absolute dollar amount limits the signal's magnitude, but the pattern of increasing purchases at higher prices suggests conviction.
Price Chart
Executive Summary
Greenwich LifeSciences CEO/CFO Snehal Patel made three open-market purchases totaling $67K over a week, increasing his stake at prices between $12.88 and $13.62. This is a standalone conviction buy by the top executive at a $197M market cap biotech with 88% analyst bullishness, representing ~0.034% of market cap — a small but symbolically significant insider vote of confidence ahead of potential pipeline catalysts for the company's breast cancer vaccine candidate GP2.
Key Financial Metrics
Key Facts
- CEO/CFO Snehal Patel purchased 5,100 shares total across three open-market buys from July 23-27, 2026
- Total purchase value: $67,000 at average price ~$13.14
- Market cap: $197M; purchases represent ~0.034% of market cap
- 88% of analysts rate the stock as Strong Buy or Buy
- No 10b5-1 plan pattern detected — trades are irregular in size and timing
Financial Impact
CEO/CFO invested $67K of personal capital at ~$13.14/share, a modest but unambiguous insider vote of confidence at a $197M market cap
Risk Factors
- Biotech pipeline risk — GP2 vaccine is still in clinical development with no approved product
- Insider purchase is only 0.034% of market cap, which is below the 0.1% threshold for materiality
- Small market cap ($197M) makes stock highly volatile and sensitive to trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001493152-26-035085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $17.01 | awaiting T+5 | — | $17.06 (+0.27%) |
Oct 26, 2026 today | DEF 14A | $17.28 | awaiting T+5 | — | $17.06 (−1.27%) |
Aug 10, 2026 11w ago | Press Release | $15.50 $17.38 | ▲ +12.13% | ▲ +12.18% | $17.06 (+10.06%) |
Jul 30, 2026 12w ago | Insider Buy | $14.02 $14.24 | ▲ +1.57% | ▼ −2.05% | $17.06 (+21.68%) |
Jul 29, 2026 12w ago | Insider Buy | $12.80 $14.39 | ▲ +12.42% | ▲ +6.89% | $17.06 (+33.28%) |
May 22, 2026 22w ago | Press Release | $27.39 $24.29 | ▲ +11.32% | ▲ +12.53% | $17.06 (+37.71%) |
Apr 22, 2026 26w ago | Press Release | $23.67 $21.60 | ▲ +8.75% | ▲ +10.22% | $17.06 (+27.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers